The project is building the first federated and fully protected global network for sharing genomics and biomedical data
integrate.ai, a SaaS company helping organizations solve the world’s most important problems without risking the world’s most sensitive data, today announced its central role in the Canadian Platform for Genomics and Precision Health (CP4GPH), funded in part by Digital. Together with partner DNAstack, the platform will help deliver better outcomes for Canadians by making it easier to derive AI-powered discoveries across networks of data in neuroscience, oncology, rare disease, infectious disease, health care, agriculture, and beyond.
“We are proud to lead innovative work through this initiative and we are indebted to participants in clinical trials that are accelerating meaningful discoveries for autistic individuals and their families.”
Scientists, clinicians, researchers and AI algorithms need large and diverse datasets to uncover innovative precision health solutions. The current approach to data centralization has made it nearly impossible to safely and accurately analyze the large amounts of data needed to make these discoveries. Ever-evolving regulations have also restricted researchers’ access to quality patient data, further limiting advances in this space.
“Traditional approaches like centralized data sharing are inefficient, insecure and impractical for sensitive health data. integrate.ai’s software enables AI and analytic work across sensitive data silos without needing to move the data, providing maximum protection and unblocking critical innovation in genomics and precision health,” said Steve Irvine, founder and CEO of integrate.ai. “Canada’s biotech industry has made a considerable impact on the global stage, and this project will put Canada at the forefront of precision health – driving innovation, enabling job creation and cultivating high-value research and discovery.”
The CP4GPH will enable privacy-preserving federated analytics and AI through integrate.ai’s technology, allowing researchers to safely activate data silos and derive insights across distributed datasets without sharing, moving, or providing direct access to data between organizations. Since the location and control of the data remains unchanged, privacy and security can be maintained and data can be utilized according to patient consent. The project will cultivate an open innovation ecosystem that additional stakeholders can plug into, and will ultimately commercialize globally-leading solutions to manage, share, analyze, and translate insights from genomics and health data.
“We are committed to creating a world of possibilities in autism research by supporting critical projects like the Canadian Platform for Genomics and Precision Health,” said Evdokia Anagnostou, VP of Research at Holland Bloorview Kids Rehabilitation Hospital. “We are proud to lead innovative work through this initiative and we are indebted to participants in clinical trials that are accelerating meaningful discoveries for autistic individuals and their families.”
By combining the latest standards for data interoperability with AI-powered technologies for federated learning, the CP4GPH is creating a new way for organizations to safely collaborate to unlock value from the world’s exponentially growing volumes of genomic and health data.
To learn more about this ground-breaking software platform, please visit their site or stop by to meet integrate.ai’s executive team during the global HIMSS conference from April 17-21, 2023 in Chicago, IL.
integrate.ai is a SaaS company helping organizations solve the world’s most important problems without risking the world’s most sensitive data. Through its safe data collaboration platform, integrate.ai empowers data science leaders to activate data silos and run federated analytics and AI workloads by moving models, not data. Armed with experience building data networks within enterprises across eight industries, integrate.ai enables organizations to safely accelerate access to secure, interoperable data and advance insights across critical use cases, including precision medicine, drug discovery, clinical trials, collaborative research, corporate data silos, risk underwriting, fraud detection, and more.